TQB3454 in mutant IDH1 advanced cholangiocarcinoma (CCA): Results of a phase I dose escalation and expansion study cohort

被引：1
|
作者：
Yuan, J. [1 ]
Zheng, Y. [2 ]
Xu, L. [3 ]
Xie, F. [4 ]
Gu, S. [5 ]
Li, Q. [6 ]
Zhang, J. [7 ]
Ba, Y. [8 ]
Huaxin, D. [9 ]
Yang, A. [10 ]
Li, J. [10 ]
Zhou, J. [11 ]
Shen, L. [11 ]
机构：
[1] Peking Univ, Dept Gastrointestinal Oncol, Canc Hosp Inst, Beijing, Peoples R China
[2] Zhejiang Univ, Dept Oncol, Affiliated Hosp 1, Hangzhou, Peoples R China
[3] Sun Yat Sen Univ, Dept Liver Surg, Canc Ctr, Guangzhou, Peoples R China
[4] Chinese PLA Naval Mil Med Univ, Dept Surg, Affiliated Hosp 3, Shanghai, Peoples R China
[5] Hunan Canc Hosp, Intervent Div, Changsha, Peoples R China
[6] SCU Sichuan Univ, Dept Oncol, Huaxi Campus, Chengdu, Peoples R China
[7] Southern Med Univ, Dept Oncol, ZhuJiang Hosp, Zhujiang, Peoples R China
[8] Tianjin Med Univ, Dept Gastroenterol, Canc Inst & Hosp, Tianjin, Peoples R China
[9] Hunan Prov Peoples Hosp, Dept Oncol, Changsha, Peoples R China
[10] CTTQ Chia Tai Tianqing Pharmaceut Grp Co Ltd, Clin Med, Lianyungang, Peoples R China
[11] Peking Univ Canc Hosp & Inst, GI Oncol Dept, Beijing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.05.292
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
286P
引用
收藏
页码：S120 / S120
页数：1
相关论文
共 50 条
  • [31] Baseline characteristics and molecular testing of Australian patients with IDH1 mutated cholangiocarcinoma: initial results from the phase IIIb ProvIDHe study
    Sim, H-W.
    McLachlan, S-A.
    Dean, A.
    Price, T. J.
    Eastgate, M.
    Rimassa, L.
    Mercade, T. Macarulla
    Malka, D.
    Gharbi, H.
    Robert, R.
    Sullivan, A.
    Vogel, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S1463 - S1463
  • [32] Ivosidenib in patients with IDH1-mutant relapsed/refractory myelodysplastic syndrome (R/R MDS): Updated enrollment and results of a phase 1 dose-escalation and expansion substudy.
    Sallman, David Andrew
    Foran, James M.
    Watts, Justin M.
    Stein, Eytan
    De Botton, Stephane
    Fathi, Amir Tahmasb
    Prince, Gabrielle T.
    Stone, Richard M.
    Patel, Prapti Arvind
    Roboz, Gail J.
    Arellano, Martha Lucia
    Erba, Harry Paul
    Pigneux, Arnaud
    Baratam, Praneeth
    Thomas, Xavier G.
    Bai, Xiaofei
    Kapsalis, Stephanie M.
    Garcia-Manero, Guillermo
    Dinardo, Courtney Denton
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [33] NCI 10129: A Phase 2 Study of the PARP inhibitor Olaparib (AZD2281) in IDH1 and IDH2 mutant advanced solid tumors
    Cecchini, Michael
    Pilat, Mary Jo
    Uboha, Nataliya
    Azad, Nilofer S.
    Cho, May
    Davis, Elizabeth J.
    Ahnert, Jordi Rodon
    Tinoco, Gabriel
    Shapiro, Geoff I.
    Khagi, Simon
    Powers, Benjamin
    Groisberg, Roman
    Drappatz, Jan
    Chen, Li
    Das, Biswajit
    Bao, Xun
    Li, Jing
    Patel, Abhijit
    Niger, Monica
    Doroshow, Deborah
    Durecki, Diane
    Boerner, Scott
    Bindra, Ranjit
    Ivy, Percy
    Shyr, Yu
    LoRusso, Patricia
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [34] The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas
    Natsume, Atsushi
    Arakawa, Yoshiki
    Narita, Yoshitaka
    Sugiyama, Kazuhiko
    Hata, Nobuhiro
    Muragaki, Yoshihiro
    Shinojima, Naoki
    Kumabe, Toshihiro
    Saito, Ryuta
    Motomura, Kazuya
    Mineharu, Yohei
    Miyakita, Yasuji
    Yamasaki, Fumiyuki
    Matsushita, Yuko
    Ichimura, Koichi
    Ito, Kazumi
    Tachibana, Masaya
    Kakurai, Yasuyuki
    Okamoto, Naoko
    Asahi, Takashi
    Nishijima, Soichiro
    Yamaguchi, Tomoyuki
    Tsubouchi, Hiroshi
    Nakamura, Hideo
    Nishikawa, Ryo
    NEURO-ONCOLOGY, 2023, 25 (02) : 326 - 336
  • [35] CLINICAL SAFETY AND ACTIVITY OF AG-120, A FIRST-IN-CLASS, POTENT INHIBITOR OF THE IDH1 MUTANT PROTEIN, IN A PHASE 1 STUDY OF PATIENTS WITH ADVANCED IDH1-MUTANT HEMATOLOGIC MALIGNANCIES
    de Botton, S.
    Pollyea, D. A.
    Stein, E. M.
    DiNardo, C.
    Fathi, A. T.
    Roboz, G. J.
    Collins, R.
    Swords, R. T.
    Flinn, I.
    Altman, J. K.
    Tallman, M. S.
    Kantarjian, H.
    Colby, K.
    Fan, B.
    Goldwasser, M.
    Prahl, M.
    Agresta, S.
    Stone, R. M.
    HAEMATOLOGICA, 2015, 100 : 214 - 215
  • [36] Molecular Profiling and Relationship with Clinical Response in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Potent Inhibitor of Mutant IDH1, in Addition to Data from the Completed Dose Escalation Portion of the Phase 1 Study
    DiNardo, Courtney
    de Botton, Stephane
    Pollyea, Daniel A.
    Stein, Eytan M.
    Fathi, Amir T.
    Roboz, Gail J.
    Collins, Robert
    Swords, Ronan T.
    Flinn, Ian W.
    Altman, Jessica K.
    Tallman, Martin S.
    Kantarjian, Hagop M.
    Derti, Adnan
    Goldwasser, Meredith
    Prahl, Malia
    Wu, Bin
    Yen, Katherine
    Agresta, Sam
    Stone, Richard M.
    BLOOD, 2015, 126 (23)
  • [37] Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study
    Wang-Gillam, Andrea
    Lim, Kian-Huat
    McWilliams, Robert
    Suresh, Rama
    Lockhart, Albert C.
    Brown, Amberly
    Breden, Marcus
    Belle, Jad I.
    Herndon, John
    Bogner, Savannah J.
    Pedersen, Katrina
    Tan, Benjamin
    Boice, Nicholas
    Acharya, Abhi
    Abdiannia, Mina
    Gao, Feng
    Yoon, Harry H.
    Zhu, Mojun
    Trikalinos, Nikolaos A.
    Ratner, Lee
    Aranha, Olivia
    Hawkins, William G.
    Herzog, Brett H.
    Denardo, David G.
    CLINICAL CANCER RESEARCH, 2022, 28 (24) : 5254 - 5262
  • [38] Clinical safety and activity in a phase I trial of AG-120, a first in class, selective, potent inhibitor of the IDH1-mutant protein, in patients with IDH1 mutant positive advanced hematologic malignancies
    Pollyea, D. A.
    de Botton, S.
    Fathi, A. T.
    Stein, E. M.
    Tallman, M. S.
    Agresta, S.
    Bowden, C.
    Fan, B.
    Prah, M.
    Yang, H.
    Yen, K.
    Stone, R. M.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 195 - 195
  • [39] A PHASE 1/1B DOSE ESCALATION AND COHORT EXPANSION STUDY OF MGC018 IN COMBINATION WITH LORIGERLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS (AST)
    Powderly, John
    Kaminker, Patrick
    Zhao, Enxu
    Casey, Denise
    Shenderov, Eugene
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A789 - A789
  • [40] UPDATED RESULTS OF A PHASE I DOSE-ESCALATION, DOSE-EXPANSION STUDY OF DISULFIRAM AND ADJUVANT TEMOZOLOMIDE FOR NEWLY DIAGNOSED GLIOBLASTOMA
    Huang, Jiayi
    Campian, Jian
    Gujar, Amit
    Tsien, Christina
    Ansstas, George
    Tran, David
    Dewees, Todd
    Kim, Albert
    Lockhart, A. Craig
    NEURO-ONCOLOGY, 2017, 19 : 5 - 5
12345